Loading
Life sciences · Observational Study
ClinicalTrials.gov · October 14, 2026
No summary has been generated for this record yet. What follows is drawn from its source metadata only.
Observational Study.
No findings were extractable from the material analysed.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
The source did not state who this applies to in practice.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
This record has not been graded across any dimension yet. Treat the label above as provisional and read the source.
What is missing. This record has no bottom line, key findings, reported figures, evidence dimensions. That is a gap in the analysis, not a judgement about the study.
Registry record from ClinicalTrials.gov (NCT03774758). This is a study registration, not published results. Lead sponsor: University of California, San Francisco. Recruitment status: RECRUITING. Study type: OBSERVATIONAL. Enrollment: 1440 participants (ESTIMATED). Conditions: Nodule Solitary Pulmonary, Non-small Cell Lung Cancer. Interventions: DIAGNOSTIC_TEST: Guardant Health ct-DNA LUNAR assay. Primary outcome measures: Sensitivity and specificity of ct-DNA LUNAR Assay , Extended CT screening follow-up defined by documentation of ≥3 years of radiographic stability and/or consensus clinical opinion by tumor board.; Prospective negative predictive value of ct-DNA LUNAR assay , Extended CT screening follow-up defined by documentation of ≥3 years of radiographic stability and/or consensus clinical opinion by tumor board.. Brief summary: This is a prospective observational study that will follow patients who undergo lung cancer screening at the San Francisco VA Medical Center, University of California, San Francisco (UCSF) Medical Center, and the San Francisco General Hospital. The proposed study will comprise of two primary populations to determine the ctDNA assay performance in a variety of clinical settings.